Blocking HMGB1 in the pathway led to inhibition in APP expression, suggesting that HMGB1 could potentially be a therapeutic target to reduce the accumulation of Aβ plaques in the brain and be effective in mitigating the risks of AD progression from METH use. Here, HMGB1 is linked to Alzheimer disease.